Drugs / WIN378
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07646587 | Jun 2026 → Dec 2027 expected | chronic obstructive pulmonary disease | Windward Bio | Recruiting | No outcome recorded |
| Phase 2 | NCT07120503 | Jul 2025 → Jul 2027 expected | asthma | Windward Bio | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Results Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study kelun-biotech.com ↗
SKB378/WIN378 produced significant and sustained effects on FEV 1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbations. |
| 2026-09-08 | Harbour BioMed (Guangzhou) Co. Ltd. | Results HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study harbourbiomed.com ↗
HBM9378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbations. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study kelun-biotech.com ↗ |
| 2026-09-08 | Harbour BioMed (Guangzhou) Co. Ltd. | HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study harbourbiomed.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WIN378 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646587 ↗ |
| Action | Inhibit | “blocking its activity” NCT07120503 ↗ |
| Modality | Monoclonal antibody | “fully human, long-acting monoclonal antibody” NCT07120503 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07120503 ↗ |
| Target | TSLP | “binds to thymic stromal lymphopoietin (TSLP)” NCT07120503 ↗ |